These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1036 related articles for article (PubMed ID: 18262431)

  • 1. Dendritic cell vaccines in melanoma: from promise to proof?
    Lesterhuis WJ; Aarntzen EH; De Vries IJ; Schuurhuis DH; Figdor CG; Adema GJ; Punt CJ
    Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cell-based immunotherapy of malignant melanoma: success and limitations.
    Tuettenberg A; Schmitt E; Knop J; Jonuleit H
    J Dtsch Dermatol Ges; 2007 Mar; 5(3):190-6. PubMed ID: 17338793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cell-based immunotherapy.
    Osada T; Clay TM; Woo CY; Morse MA; Lyerly HK
    Int Rev Immunol; 2006; 25(5-6):377-413. PubMed ID: 17169781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of dendritic cells for cancer vaccination.
    Esche C; Shurin MR; Lotze MT
    Curr Opin Mol Ther; 1999 Feb; 1(1):72-81. PubMed ID: 11249687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model.
    Berinstein NL
    Ann N Y Acad Sci; 2009 Sep; 1174():107-17. PubMed ID: 19769743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients.
    Verdijk P; Aarntzen EH; Lesterhuis WJ; Boullart AC; Kok E; van Rossum MM; Strijk S; Eijckeler F; Bonenkamp JJ; Jacobs JF; Blokx W; Vankrieken JH; Joosten I; Boerman OC; Oyen WJ; Adema G; Punt CJ; Figdor CG; de Vries IJ
    Clin Cancer Res; 2009 Apr; 15(7):2531-40. PubMed ID: 19318472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cell vaccination as a treatment modality for melanoma.
    Eubel J; Enk AH
    Expert Rev Anticancer Ther; 2009 Nov; 9(11):1631-42. PubMed ID: 19895246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.
    Shu S; Cochran AJ; Huang RR; Morton DL; Maecker HT
    Cancer Metastasis Rev; 2006 Jun; 25(2):233-42. PubMed ID: 16770535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
    Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E
    J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic cells for specific cancer immunotherapy.
    Meidenbauer N; Andreesen R; Mackensen A
    Biol Chem; 2001 Apr; 382(4):507-20. PubMed ID: 11405216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic cell vaccines in acute leukaemia.
    Duncan C; Roddie H
    Best Pract Res Clin Haematol; 2008 Sep; 21(3):521-41. PubMed ID: 18790453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cell-based immunotherapy in myeloid leukaemia: translating fundamental mechanisms into clinical applications.
    van de Loosdrecht AA; van den Ancker W; Houtenbos I; Ossenkoppele GJ; Westers TM
    Handb Exp Pharmacol; 2009; (188):319-48. PubMed ID: 19031033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing dendritic cell-based immunotherapy for cancer.
    Zhong H; Shurin MR; Han B
    Expert Rev Vaccines; 2007 Jun; 6(3):333-45. PubMed ID: 17542749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Taming cancer by inducing immunity via dendritic cells.
    Palucka AK; Ueno H; Fay JW; Banchereau J
    Immunol Rev; 2007 Dec; 220():129-50. PubMed ID: 17979844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer.
    Antonia SJ; Mirza N; Fricke I; Chiappori A; Thompson P; Williams N; Bepler G; Simon G; Janssen W; Lee JH; Menander K; Chada S; Gabrilovich DI
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):878-87. PubMed ID: 16467102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Towards a standardized protocol for the generation of monocyte-derived dendritic cell vaccines.
    Erdmann M; Schuler-Thurner B
    Methods Mol Biol; 2010; 595():149-63. PubMed ID: 19941110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic dendritic cell vaccination of patients with renal cell carcinoma.
    Berntsen A; Geertsen PF; Svane IM
    Eur Urol; 2006 Jul; 50(1):34-43. PubMed ID: 16675096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of CD34+ progenitor-derived dendritic cells pulsed with tumor cell lysate for a vaccination strategy in children with malignant solid tumors and a poor prognosis.
    Ackermann B; Tröger A; Glouchkova L; Körholz D; Göbel U; Dilloo D
    Klin Padiatr; 2004; 216(3):176-82. PubMed ID: 15175963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cell-based vaccines in breast and gynaecologic cancer.
    Hernando JJ; Park TW; Kuhn WC
    Anticancer Res; 2003; 23(5b):4293-303. PubMed ID: 14666641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melanoma cancer vaccines and anti-tumor T cell responses.
    Vujanovic L; Butterfield LH
    J Cell Biochem; 2007 Oct; 102(2):301-10. PubMed ID: 17647270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.